Physician profile
David A Buck
NPI 1952377194
$12,811.88
in general payments reported to CMS, 2019-2025
11 companies · $1,858 in 2025
The $1,858 reported for 2025 was more than what 89% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,807 · 2021: $1,980 · 2022: $231 · 2023: $194 · 2024: $1,743 · 2025: $1,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,663 · Travel and Lodging: $1,633 · Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,662.50 |
| Travel and Lodging | $1,633.17 |
| Food and Beverage | $498.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $6,721.79 | 2019 | |
| Progenics Pharmaceuticals, INC. | $2,076.86 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $1,904.49 | 2022-2025 | |
| Ge Healthcare | $1,835.49 | 2025 | |
| Gt Medical Technologies, INC | $94.98 | 2023 | Gammatile |
| Advanced Accelerator Applications | $72.42 | 2019 | |
| Tactile Systems Technology INC | $48.97 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Ethicon US, LLC | $44.19 | 2023 | Neuwave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.69 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.